While moderate hypofractionation EBRT is the preferred regimen for low-volume metastatic disease, ultra-hypofractionation EBRT has acceptable efficacy and toxicity profiles, according to the NCCN guidelines. Conventional fractionation ERBT and SBRT have demonstrated acceptable efficacy and toxicity profiles for all NCCN risk groups. For regional disease, moderate hypofractionation EBRT and conventional EBRT may be appropriate. Brachytherapy monotherapy has acceptable efficacy and toxicity for very low, low, and favorable intermediate NCCN risk groups.
Learn more about radiation treatment of metastatic and advanced prostate cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Evelyn S. Marienberg. Fast Five Quiz: Radiation Therapy for Metastatic and Advanced Prostate Cancer - Medscape - Nov 08, 2022.